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ABSTRACT
Background and the purpose of  the study: Hospital-acquired methicillin-resistant Staphylococcus   
aureus (MRSA) has been a major problem worldwide in chemotherapy of infection disease. 
This study was designed to assess the enhancing effects of a new group of dihydropyridine-3,5-
dicarboxamides, in combination with cloxacillin with distinctly different mechanisms of action 
against MRSAs.
Material and methods:  Dihydropyridine-3,5-dicarboxamides with 2-methylsulfonylimidazole 
at 4 position 6a-k were synthesized by  the reaction of corresponding aldehyde 5 with different 
N-aryl acetoacetamides 3 in  the presence of ammonium hydroxide. Agar disc diffusion method 
was used to determine the antibacterial and potentiating activity of different synthetic compounds 
in the presence and absence of cloxacillin to evaluate their activity as modulators of multidrug-
resistant (MDR).
Results and major conclusion: The antibacterial effect of cloxacillin was enhanced by compounds 
6g and 6h against cloxacillin-resistant strains (MRSA1 and MRSA2). The potentiation was found 
to be statistically significant (p<0.01). Compound 6g at concentration of 1000 µg/disc, caused a 
329 percent potentiation of the activity of cloxacillin against MRSA1.
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INTRODUCTION
One of the major problems in hospitals and community 
is the emergence and spread of MDR organisms such 
as Staphylococcus aureus that display resistance to 
methicillin; cloxacillin and other narrow-spectrum 
beta-lactamase-resistant  penicillin  antibiotics  as 
well  as  cephalosporins  (1,  2).  These  bacteria  are 
labeled  as  methicillin-resistant  Staphylococcus 
aureus  (MRSA).  The  hospital  MRSA  is  usually 
multi-drug resistant, demonstrating resistant to other 
classes of antibiotics. Overuse of antibiotics and the 
use of improper drugs may be some of the reasons 
for development of virulent strains. Infections with 
these organisms represent a serious challenge to the 
practitioner as therapeutic options are limited and 
associated mortality is high (3). Many institutions 
have observed an increase in blood culture isolates 
of MRSA over the past two decades.
There is a clear and urgent need to discover and 
develop new effective and non-toxic drugs that are 
able to overcome MDR. Some of the medicines have 
been reported to enhance the antibacterial activity 
of  different  antibiotics  against  different  resistant 
strains (4-6). 1,4-Dihydropyridine derivatives have 
been found as multidrug-resistance (MDR) reversal 
agents in tumor cells (7). In continuing investigation 
on 1,4-dihydropyridine compounds (8, 9) and  to 
characterize new synthetic compounds with activity 
as  modulators  of  MDR  in  Staphylococcus  aureus 
(10),  some  new  N,  N-diaryl-2,6-dimethyl-4-(2-
methyl-sulfonylimidazol5-yl)-1,4-dihydropyridine-
3,5-dicarboxamide derivatives were synthesized and 
their antibacterial properties were evaluated.
 MATERIAL AND METHODS
Chemistry
Melting  points  were  determined  using  a  Kofler 
hot stage apparatus and are uncorrected.  1H-NMR 
spectra  were  run  on  a  Bruker  FT-80  and  FT-500 
spectrometers (Brukers, Rheinsteetteen, Germany). 
TMS was used as internal standard. Mass spectra 
were measured with a Finnigan TSQ-70 spectrometer 
(Finnigan Mat, Bremen, Germany). Infrared spectra were acquired on a Nicolet 550-FTIR spectrometer 
(Maidson, WI, USA). 
The  synthesis  of  1,4-dihydropyridine  derivatives 
6a-k  was  achieved  following  the  steps  outlined 
in  Scheme  1.  Reaction  of  amine  1  with  2,2,6-
trimethyl-4H-1,3-dioxine-4-one  2  afforded  the 
corresponding  acetoactamide  3  (76-92%  yield) 
(11).  Oxidation  of  4  with  manganese  (IV)  oxide 
in  chloroform  afforded  the  desired  aldehyde  5  in 
90%  yield  (12,  13).  Symmetrical  dihydropyridine 
analogues  6  were  prepared  by  classical  Hantzsch 
condensation in which the aldehyde 5 was reacted 
with the corresponding N-aryl actoacetamide 3a-k 
and ammonium hydroxide in ethanol.
  
Antibacterial  and  enhancement  effect  of  the 
synthesized compounds
Minimum inhibitory concentration of cloxacillin was 
determined  by  conventional  agar  dilution  method 
against  2  clinically  isolated  cloxacillin-resistant 
Staphylococcus aureus.
For  determination  of  enhancing  effect  of  the 
synthetic compounds, a stock solution of cloxacillin 
was prepared in dimethylsulfoxide (DMSO; 1 ml) 
which was added to molten Mueller-Hinton (MH) 
agar  (19  ml)  at  50°C  to  give  the  sub-inhibitory 
concentration of 12.5 µg/ml. The bacteria inocula 
were  prepared  by  suspending  overnight  colonies 
from MH agar media in 0.85 % saline. The inocula 
were adjusted photometricaly at 600 nm to a cell 
density equivalent to approximately 0.5 McFarland 
standard (1.5×108 CFU/ml) (10, 14). MH agar plates 
were seeded individually with bacterial suspensions 
using a sterile cotton swab. Two-fold dilution of the 
test compounds were prepared in DMSO and 20 µl of 
each dilute was added to blank discs to give the final 
concentrations of 1000, 500, 250 and 125 µg/disc. Discs 
containing synthetic compounds were applied on the 
surface of seeded MH agar plates. Similar loaded discs 
were applied to agar plates without any antibacterial 
agents. To insure that the solvent had no effect on 
bacterial growth, a control test was performed with 
test medium supplemented with DMSO at the same 
dilutions as used in the experiment.  Blank  discs 
containing  20µl  DMSO  were  used  as  negative 
controls. The plates were incubated at 30-35°C for 
18 hrs. After incubation, the mean inhibition zone 
diameter  for  each  concentration  was  determined. 
The  diameters  of  inhibition  zones  produced  due 
to  individual  and  combined  effects  of  effective 
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6a 52 238-239
IR  (KBr):  1648(NHC=O),  1HNMR  (DMSO-d6)  δ:  9.52  (s, 
2H, NH), 8.22 (s, 1H, N1-H DHP), 7.56 (d, J=7.6 Hz, 4H, 
aromatic),  7.26  (t,  J=7.6  Hz,  4H,  aromatic),  7.02  (t,  J=7.6 
Hz, 2H, aromatic), 6.98 (s, 1H, C4-H imidazole), 5.15 (s, 1H, 
C4-H DHP), 3.84 (s, 3H,NCH3), 3.13 (s, 3H, SO2CH3), 2.09 
(s, 6H, 2,6 CH3). Mass: m/z (%) 504 (M+-1, 0.5%), 385 (43), 
371 (98), 292 (100), 253 (98), 186 (70), 160 (97), 119 (64).
6b
F
54 230-231
IR  (KBr):  1649(NHC=O), 1 HNMR  (DMSO-d6)  δ:  9.27 
(s,  2H,  N-H),  8.47  (s,  1H,  N1-H  DHP),  7.14  (m,  8H, 
aromatic),  6.84  (s,  1H,  H-C4 imidazole),  5.14  (s,  1H,H-C4 
DHP),  3.87  (s,  3H,  N-CH3),  3.40  (s,  3H,  SO2-CH3),  2.15 
(s, 6H, 2,6 CH3). Mass: m/z (%) 541 (M+, 3), 463 (47), 325 
(61),  292  (100),  214  (72),  188  (100),  137  (100),  80  (100).
6c
Cl
44 231-232
IR (KBr):  1654(NHC=O), 1HNMR (DMSO-d6) δ:  9.08 (s, 2H, 
N-H), 8.46 (s, 1H, N1-H DHP), 7.50 (dd, J=8Hz, J=1.5 Hz, 2H, 
aromatic), 7.45 (dd, J=8Hz, J=1.5 Hz, 2H, aromatic), 7.29 (td, 
J=8Hz, J=1.5 Hz, 2H, aromatic), 7.17 (td, J=8Hz, J=1.5 Hz, 
2H, aromatic), 6.87 (s, 1H, C4-H imidazole), 5.16 (s, 1H, - C4-H   
DHP), 3.90 (s, 3H, N-CH3), 3.31 (s, 3H, SO2-CH3), 2.20 (s, 
6H, 2,6  CH3), Mass: m/z (%) 574 (M++1, 7), 495 (48), 448 
(40), 420 (27), 341 (100), 266 (100), 186 (100), 106 (100).
6d Cl 51 248-249
IR (KBr):  1629(NHC=O), 1HNMR (DMSO-d6) δ: 9.65 (s,2H, 
N-H), 8.44 (s, 1H, N1-H DHP), 7.60 (d, J=9 Hz, 4H, aromatic), 
7.30 (d, J=9 Hz, 4H, aromatic), 6.82 (s, 1H, C4-H imidazole), 
5.12 (s, 1H, C4-H  DHP), 3.83 (s, 3H, N-CH3), 3.31 (s, 3H, SO2-
CH3), 2.09 (s, 6H, 2,6 CH3). Mass: m/z (%) 573 (M+, 2), 495 
(32), 342 (58), 295 (100), 226 (60), 188 (100), 98 (100), 55 (100).
6e
Cl Cl
68 211-212
IR (KBr): 1619(NHC=O), 1HNMR (DMSO-d6) δ: 9.35 (bs, 2H, 
NH), 8.53 (s, 1H, N1-H DHP), 7.45 (m, 4H, aromatic), 7.31 
(t, 2H, aromatic), 6.86 (s, 1H, C4-H imidazole), 5.17 (s, 1H, 
C4 –H  DHP), 3.89 (s, 3H, NCH3), 3.34 (s, 3H, SO2CH3), 2.19 
(s, 6H, 2,6 CH3). Mass: m/z (%) 644 (M++3, 3), 641 (M+,0.5), 
563 (28), 482 (60), 375 (100), 322 (85), 266(100), 160 (100).
6f
Cl
Cl
88 228-229
IR (KBr):  1622(NHC=O), 1HNMR (DMSO-d6) δ: 9.15 (s, 2H, 
NH), 8.62 (s, 1H, N1-H DHP), 7.69 (d, J=2.5 Hz, 2H, C6 -H   
phenyl), 7.50 (d, J=9 Hz, 2H, C3 -H phenyl), 7.26 (dd, J=9 Hz, 
J=2.5 Hz, 2H, C4-H phenyl), 6.87 (s, 1H, C4-H imidazole), 5.14 
(s, 1H, C4-H  DHP), 3.90 (s, 3H, NCH3), 3.33 (s, 3H, SO2CH3), 
2.20 (s, 6H, 2,6 CH3). Mass: m/z (%) 644 (M++3, 3), 641 (M+,1), 
565 (49), 482 (58), 375 (100), 266 (100), 186(100), 109 (100).
6g Cl
Cl
89 263-264
IR (KBr): 1624(NHC=O), 1HNMR (DMSO-d6) δ: 9.80 (s, 2H, 
NH), 8.59 (s, 1H, N1-H DHP), 7.94 (s, 2H, aromatic), 7.53 
(s, 4H, aromatic), 6.81 (s, 1H, C4-H imidazole), 5.11 (s, 1H, 
C4-H  DHP), 3.812 (s, 3H, NCH3), 3.33 (s, 3H, SO2CH3), 2.10 
(s, 6H, 2,6 CH3). Mass: m/z (%) 644 (M++3, 2), 641 (M+,0.5), 
375 (28), 321 (45), 266 (67), 188 (100), 159(100), 106 (100).
6h Cl
Cl
Cl
98 152-153
IR  (KBr):  1670(NHC=O), 1HNMR  (DMSO-d6)  δ:  9.23  (s, 
2H, NH), 8.65 (s, 1H, N1-H DHP), 7.89 (s, 2H, aromatic), 
7.87  (s,2H, aromatic), 6.86 (s, 1H, C4-H imidazole), 5.12 (s, 
1H, C4-H  DHP), 3.89 (s, 3H, NCH3), 3.34 (s, 3H, SO2CH3), 
2.20 (s, 6H, 2,6 CH3). Mass: m/z (%) 709 (M+, 7), 516 (2), 
410 (24), 295 (20), 223 (64), 198 (32), 153(100), 109 (100).
Table 1. Physical data for compounds 6a-k
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6i NO2 67 163-164
IR (KBr):  1680(NHC=O), 1HNMR (DMSO-d6) δ: 10.14 (s, 2H, 
NH), 8.74 (s, 1H, N1-H DHP), 8.18 (d, J=9 Hz, 4H, aromatic), 
7.83 (d, J=9 Hz, 4H, aromatic), 6.84 (s, 1H, C4-H imidazole), 
5.17 (s, 1H, C4-H   DHP), 3.84 (s, 3H, NCH3), 3.32 (s, 3H, 
SO2CH3), 2.14 (s, 6H, 2,6 CH3). Mass: m/z (%) 595 (M+, 2), 564 
(9), 456 (40), 318 (17), 292 (100), 266 (30), 212(33), 108 (68).
6j
NO2
NO2
97 200-201
IR (KBr): 1680(NHC=O), 1HNMR (DMSO-d6) δ: 8.64 (d, 
J=2.5 Hz, 2H, C3-H phenyl), 8.45 (dd, J=9 Hz, J=2.5 Hz, 
2H,  C5-H  phenyl),  7.89  (d,  J=9  Hz,  2H,  C6-H  phenyl), 
6.84  (s,  1H,  C4-H  imidazole),  5.11  (s,  1H,  C4-H    DHP), 
3.81  (s,  3H,  NCH3),  3.29  (s,  3H,  SO2CH3),  2.27  (s,  6H, 
2,6  CH3).  Mass:  m/z  (%)  685  (M+,  2),  502  (37,  475 
(12),  411  (10),  318  (15),  293  (100),  183  (27),  81  (40).
6k O
O
41 200-202
IR  (KBr):  1623(NHC=O), 1HNMR  (DMSO-d6)  δ:9.42  (s, 
2H, NH), 8.14 (s, 1H, N1-H DHP), 7.24 (d, J=2 Hz, 2H, 
aromatic), 6.95 (dd, J=8.3 Hz, J=2 Hz 2H, aromatic), 6.82 
(s, 1H, C4-H imidazole), 6.80 (d, J=8.3 Hz, 2H, aromatic), 
5.95  (s,  2H,  O-CH2-O),  5.09  (s,  1H,  C4-H    DHP),  3.82 
(s,  3H,  NCH3),  3.37  (s,  3H,  SO2CH3),  2.07  (s,  6H,  2,6 
CH3). Mass: m/z (%) 685 (M+-1, 18), 434 (21), 394 (28), 
308  (100),  258  (63),  180  (100),  109  (100),  50  (100).
compounds were recorded. The increase in the surface 
area  (πr2)  due  to  a  combination  of  effects  was 
statistically evaluated by determining student’s t-test 
for its level of significance (15).
General procedure for the synthesis of N, N′-diaryl-
2,6-dimethyl-4-(2-methylsulfonyl-1-methylimidazol-
5-yl)-1,4-dihydropyridine-3,5-dicarboxamides         
(6a-k ).
A  solution  of  ammonium  hydroxide  (26%,  0.5 
ml) was added to a stirring solution of compound 
4  (240  mg,  1.26  mmoles)  and  corresponding 
N-arylacetoacetamide 3 (2.54 mmoles) in methanol 
(5 ml). The mixture was protected from light and 
refluxed  under  argon  overnight.  After  cooling 
the  precipitate  was  filtered  and  crystallized  from 
methanol to give the title compounds 6.
The physical data for compounds 6a-k are given in 
table 1.
RESULT  AND  DISCUSSION 
The  MIC  value  of  50  µg/ml  for  cloxacillin  was 
obtained  by  agar  dilution  method  for  two 
clinically isolated cloxacillin-resistant organisms 
(MRSA1, MRSA2). A sub-inhibitory concentration 
of cloxacillin (12.5 µg/ml) was selected for further 
experiments. The antibacterial activity of synthetic 
compounds  was  evaluated  against  MRSA1  and 
MRSA2.  No  inhibitory  effect  was  observed  at 
all  concentrations  ≤1000  µg/disc.  Synthesized 
compounds were evaluated for bacterial resistance 
modifying  activity  of  cloxacillin  against  two 
MRSA strains using the agar disc diffusion method. 
Compound  6g  showed  enhancing  effect  with 
sub-inhibitory concentration of cloxacillin (12.5 µg/ml) 
at  all  tested  concentrations  and  compound  6h 
enhanced  antimicrobial  activity  of  cloxacillin 
at concentration of 250 µg/disc or higher. None 
of  the  other  synthetic  compounds  showed  any 
effect. As cloxacillin was used in a sub-inhibitory 
concentration  (12.5  µg/ml)  and  compounds  6g 
and  6h  did  not  show  any  antibacterial  activity 
in the absence of cloxacillin, the appearance of 
inhibition  zones  in  combination  of  cloxacillin 
and synthetic compounds indicated the enhancing 
effect of the compounds and it was found to be 
statistically significant (p<0.01).
Compound 6g significantly restored the bacterial 
sensitivity to the antibiotic which was showed 330 
percent increase in the inhibition zone area on the 
cloxacillin supplemented plates when applied in 
1000 µg/ml. However in the lower concentration 
of 6g (500 µg/ml) against MRSA1 and at 1000 µg/ml 
and  500  µg/ml  against  MRSA2  the  inhibition 
zones  showed  190-250  percent  potentiation 
increase. Compound 6h showed enhancing effect 
at concentrations of 250 µg/ml or higher (60-150 
percent  potentiation).  The  results  demonstrated 
that  modification  of  classical  structure  of  3,5-
diester  of  1,4-dihydropyridines  to  3,5-diamides 
could  be  a  good  way  to  combat  cloxacillin 
resistant strains. Comparison of the activities of 
symmetrical amides indicates that the presence of 
electron withdrawing groups on  the phenyl ring 
is  essential  for  enhancement  of  the  activity  of 
cloxacillin. It seems that presence of halogen at 3 
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structure resulted in enhancement of  the activity. 
However existence of a substitute on ortho position 
of phenyl reduced the effect. It is noteworthy to 
mention that the cause of enhancing effect is not 
known and require further investigation. Though 
several inverstigations have been carried out to 
overcome the microbial resistance by combination 
of synthetic and natural compounds with different 
antibiotics against resistant bacterial strains (4-6, 
10),  this paper is the first report on the potentiating 
effect of cloxacillin antibacterial activity with 1,4-
dihydropyridine derivatives. It is also of interest to 
continue this study by modifying other parts of the 
structure in order to find more potent modulating 
agents.  
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Table 2. Increase (%) in effects of cloxacillin with effective synthetic compounds compared with their individual activity based on the 
surface area of inhibition zone.
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